Evidence map›Paper›PMID 33971152›Full record

Trial reportLancet (London, England)2021

Ashesh B Jani, Eduard Schreibmann, Subir Goyal, Raghuveer Halkar, Bruce Hershatter, Peter J Rossi, Joseph W Shelton, Pretesh R Patel, Karen M Xu, Mark Goodman and 9 more

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Lancet (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01666808 (Advanced Molecular Imaging With Anti-3-[18F]FACBC PET-CT to Improve the Selection and Outcomes of Prostate Cancer Patients Receiving Post-prostatectomy Radiotherapy), which is not on this map. Cited by 91 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
21.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01666808 phase2 / phase3completednot on this map

Advanced Molecular Imaging With Anti-3-[18F]FACBC PET-CT to Improve the Selection and Outcomes of Prostate Cancer Patients Receiving Post-prostatectomy Radiotherapy

TypeinterventionalSponsorEmory UniversityRan2012 to 2022Enrolled165ConditionsProstate CancerArmsFACBC, Radiation therapy
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 1 synthesis or guideline pooled it, 178 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. An intra-patient contemporaneous comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026
    Trial
  4. [European urology · 2026
    Trial
  5. Trial
  6. Trial
  7. Randomized Trial of Conventional Versus Conventional Plus Fluciclovine (International journal of radiation oncology, biology, physics · 2022
    Trial
  8. Volumetric Changes and Acute Toxicity WithPractical radiation oncology
    Trial
  9. Trial
  10. Review
  11. Observational
  12. Observational
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. A Phase 1 Trial of Image Guided Risk Volume-Adapted Postprostatectomy Radiation Therapy.International journal of radiation oncology, biology, physics · 2025
    Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Ashesh B JaniDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA. Electronic address: abjani@emory.edu.
Eduard SchreibmannDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Subir GoyalBiostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Raghuveer HalkarDepartment of Radiology and Imaging Sciences, Emory University, Atlanta GA, USA.
Bruce HershatterDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Peter J RossiDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Joseph W SheltonDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Pretesh R PatelDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Karen M XuDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Mark GoodmanDepartment of Radiology and Imaging Sciences, Emory University, Atlanta GA, USA.
Viraj A MasterDepartment of Urology, Emory University, Atlanta GA, USA.
Shreyas S JoshiDepartment of Urology, Emory University, Atlanta GA, USA.
Omer KucukDepartment of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Bradley C CarthonDepartment of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Mehmet A BilenDepartment of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Olayinka A Abiodun-OjoDepartment of Radiology and Imaging Sciences, Emory University, Atlanta GA, USA.
Akinyemi A AkintayoDepartment of Radiology and Imaging Sciences, Emory University, Atlanta GA, USA.
Vishal R DhereDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
David M SchusterDepartment of Radiology and Imaging Sciences, Emory University, Atlanta GA, USA.
Emory University · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Molecular Imaging with FACBC PET-CT to Improve Post prostatectomy RadiotherapyR01CA169188 · NCI · EMORY UNIVERSITY · PI JANI, ASHESH, SCHUSTER, DAVID MICHAEL · 2012 to 2016
$2.1M
NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA169188
6 · The paper itself

Abstract

backgroundMolecular imaging is increasingly used to guide treatment decisions and planning in prostate cancer. We aimed to evaluate the role of

methodsIn EMPIRE-1, a single-centre, open-label, phase 2/3 randomised controlled trial, patients with prostate cancer with detectable PSA after prostatectomy and negative conventional imaging (no extrapelvic or bone findings) were randomly assigned in a 1:1 ratio to radiotherapy directed by conventional imaging alone or to conventional imaging plus

findingsFrom Sept 18, 2012, to March 4, 2019, 165 patients were randomly assigned, with median follow-up of 3·52 years (95% CI 2·98-3·95). PET findings resulted in four patients in the

interpretationInclusion of

fundingNational Institutes of Health/National Cancer Institute, Blue Earth Diagnostics, and Winship Cancer Institute of Emory University.

Indexed as

Positron Emission Tomography Computed TomographyAdenocarcinomaAgedCarboxylic AcidsCyclobutanesHumansMagnetic Resonance ImagingMaleMiddle AgedProstatectomyProstatic NeoplasmsRadiography, InterventionalSalvage TherapyCarboxylic AcidsCyclobutanesfluciclovine F-18

Identifiers

PMID33971152
PMCPMC8279109
OpenAlexW3159813235

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.